Pharma & Earnings
Pfizer Beats Profit Estimates on Strong Eliquis Demand
What’s happening
Pfizer reported better-than-expected first-quarter profit, driven by strong demand for Eliquis and core medicines.
What’s changing / Business impact
-
Shift from COVID-driven revenue → core portfolio growth.
-
Growth led by cardiovascular and oncology drugs.
-
Stabilization of pharma earnings.
Why this matters
This is a post-pandemic pharma transition signal.
This shows:
-
COVID revenue is no longer the primary driver.
-
Pharma companies are stabilizing around core therapies.